PubMed ID:
21482964
Public Release Type:
Journal
Publication Year: 2011
Affiliation: Rhode Island Hospital, 110 Lockwood Street, Providence, RI 02903, USA. abostom@lifespan.org
DOI:
https://doi.org/10.1161/CIRCULATIONAHA.110.000588
Authors:
Bostom AG,
Carpenter MA,
Cole E,
Gravens-Mueller L,
House AA,
Hunsicker L,
Jacques PF,
Kew C,
Kusek JW,
Levey AS,
McKenney JL,
Pacheco-Silva A,
Pesavento T,
Pfeffer MA,
Pirsch J,
Selhub J,
Smith S,
Solomon S,
Weir M
Studies:
Folic Acid for Vascular Outcome Reduction in Transplantation Trial
Kidney transplant recipients, like other patients with chronic kidney disease, experience excess risk of cardiovascular disease and elevated total homocysteine concentrations. Observational studies of patients with chronic kidney disease suggest increased homocysteine is a risk factor for cardiovascular disease. The impact of lowering total homocysteine levels in kidney transplant recipients is unknown.